Bristol-Myers Squibb Company – Product Pipeline Review – 2014 Reference Code: GMDHC05245CDB Publication Date: JUN 2014 Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Bristol-Myers Squibb Company – Product Pipeline Review Table of Contents Table of Contents ....................................................................................................................................................................... 2 List of Tables ....................................................................................................................................................................... 12 List of Figures ...................................................................................................................................................................... 12 Bristol-Myers Squibb Company Snapshot.................................................................................................................................. 13 Bristol-Myers Squibb Company Overview ............................................................................................................................. 13 Key Information ................................................................................................................................................................... 13 Key Facts ............................................................................................................................................................................ 13 Bristol-Myers Squibb Company – Research and Development Overview .................................................................................... 14 Key Therapeutic Areas ......................................................................................................................................................... 14 Bristol-Myers Squibb Company – Pipeline Review ..................................................................................................................... 23 Pipeline Products by Stage of Development.......................................................................................................................... 23 Pipeline Products – Monotherapy ......................................................................................................................................... 24 Pipeline Products – Combination Treatment Modalities ......................................................................................................... 25 Pipeline Products – Partnered Products................................................................................................................................ 26 Partnered Products/Combination Treatment Modalities ..................................................................................................... 27 Pipeline Products – Out-Licensed Products .......................................................................................................................... 29 Out-Licensed Products/Combination Treatment Modalities ............................................................................................... 30 Bristol-Myers Squibb Company – Pipeline Products Glance ....................................................................................................... 33 Bristol-Myers Squibb Company – Late Stage Pipeline Products............................................................................................. 33 Pre-Registration Products/Combination Treatment Modalities ........................................................................................... 33 Phase III Products/Combination Treatment Modalities ...................................................................................................... 33 Bristol-Myers Squibb Company – Clinical Stage Pipeline Products ........................................................................................ 34 Phase II Products/Combination Treatment Modalities ....................................................................................................... 34 Phase I Products/Combination Treatment Modalities ........................................................................................................ 37 Bristol-Myers Squibb Company – Early Stage Pipeline Products ........................................................................................... 40 IND/CTA Filed Products/Combination Treatment Modalities .............................................................................................. 40 Preclinical Products/Combination Treatment Modalities .................................................................................................... 41 Discovery Products/Combination Treatment Modalities ..................................................................................................... 43 Bristol-Myers Squibb Company – Drug Profiles ......................................................................................................................... 44 (atazanavir sulfate + cobicistat) ............................................................................................................................................ 44 Product Description ......................................................................................................................................................... 44 Mechanism of Action ....................................................................................................................................................... 44 R&D Progress ................................................................................................................................................................. 44 apixaban ............................................................................................................................................................................. 45 Product Description ......................................................................................................................................................... 45 Mechanism of Action ....................................................................................................................................................... 45 R&D Progress ................................................................................................................................................................. 45 asunaprevir ......................................................................................................................................................................... 46 Product Description ......................................................................................................................................................... 46 Mechanism of Action ....................................................................................................................................................... 46 R&D Progress ................................................................................................................................................................. 46 asunaprevir + daclatasvir ..................................................................................................................................................... 48 Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Bristol-Myers Squibb Company – Product Pipeline Review Product Description ......................................................................................................................................................... 48 Mechanism of Action ....................................................................................................................................................... 48 R&D Progress ................................................................................................................................................................. 48 daclatasvir ........................................................................................................................................................................... 50 Product Description ......................................................................................................................................................... 50 Mechanism of Action ....................................................................................................................................................... 50 R&D Progress ................................................................................................................................................................. 50 (daclatasvir + asunaprevir + beclabuvir) ................................................................................................................................ 52 Product Description ......................................................................................................................................................... 52 Mechanism of Action ....................................................................................................................................................... 52 R&D Progress ................................................................................................................................................................